Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2025 07:30 ET | Source: Cytokinetics, Incorporated

Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced upcoming presentations, including three Late Breaking Science presentations...
October 29, 2025 14:00 ET | Source: Circle Cardiovascular Imaging Inc.

Circle CVI Announces FDA Clearance for cvi42 | Plaque for Coronary Artery Disease Evaluation

Circle CVI has received FDA 510(k) clearance for cvi42 | Plaque, its AI-enabled coronary plaque analysis solution.
October 29, 2025 05:00 ET | Source: Royal Philips

Late-breaking iMODERN findings presented at TCT 2025 and published in the New England Journal of Medicine highlight new evidence to guide treatment choices for heart attack patients

October 29, 2025 3-Year data from the largest global trial to date using Class I, Level A iFR in heart attack patients shows treating additional stenoses in the same procedure showed no significant...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical ogłasza przełomowe wyniki badań klinicznych DynamX® Bioadaptor – wskazujące na niemal 50% redukcję częstości występowania nieporządanych incydentów wieńcowych w porównaniu do obecnego standardu leczenia PCI

Wyniki zaprezentowano podczas konferencji Transcatheter Cardiovascular Therapeutics (TCT) 2025 w San Francisco, 27 października 2025 r. DynamX® bioadaptor to pierwsza technologia interwencyjna, która...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical annuncia risultati clinici “late-breaking” significativi per DynamX® Bioadaptor che dimostrano una riduzione vicina al 50% dei tassi di eventi coronarici rispetto all’ attuale standard di cura per l’angioplastica coronarica p

I risultati sono stati presentati durante il congresso annuale sulle terapie cardiovascolari transcatetere (TCT) tenutosi a San Francisco il 27 ottobre 2025. Il DynamX® Bioadaptor è la prima...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP

Les résultats ont été présentés lors de la Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 à San Francisco, le 27 octobre 2025 Le DynamX® Bioadaptor est la première technologie...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical anuncia resultados clínicos recientes y significativos sobre el Bioadaptador DynamX® que demuestran una reducción de casi el 50 % en las tasas de acontecimiento coronarios en comparación con el tratamiento de referencia actua

Los resultados se presentaron en el congreso Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 en San Francisco (EE. UU.) el 27 de octubre de 2025 El Bioadaptador DynamX® es la primera...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical gibt klinische Late-Breaking-Ergebnisse für DynamX® Bioadaptor bekannt, die eine signifikante Reduzierung von koronaren Ereignisraten um nahezu 50 % gegenüber dem aktuellen PCI-Behandlungsstandard zeigen

Die Ergebnisse wurden bei der Transcatheter Cardiovascular Therapeutics (TCT)-Konferenz 2025 in San Francisco am 27. Oktober 2025 vorgestellt. Der DynamX® Bioadaptor ist die erste interventionelle...
October 27, 2025 17:00 ET | Source: Elixir Medical Corporation

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to...
October 23, 2025 07:00 ET | Source: George Medicines

TRIDENT, a dedicated stroke outcomes trial in patients with a history of intracerebral hemorrhage (ICH), demonstrates the potential advantages of intensive blood pressure treatment with low-dose triple combination therapyTRIDENT, a dedicate

GMRx2 significantly reduced the risk of recurrent stroke when added to standard of care compared to placeboTrial results were presented during a plenary session of the World Stroke Congress 2025...